Micro Text Module #4 with downloadable slides

Optimizing Outcomes and QoL Through Effective Management of ADC-Associated Toxicities

Share

Program Content

Activities

  • TROP2 Targeted Therapy: Module
    TROP-2–Targeted Therapy: Redefining the Therapeutic Landscape in HER2-Negative Breast Cancer
    Text Module
    Congratulations: You achieved a completion on 04/09/2022

    Released: February 22, 2024

    Expires: February 21, 2025

  • TROP2 Targeted Therapy: Slides
    TROP-2–Targeted Therapy: Redefining the Therapeutic Landscape in HER2-Negative Breast Cancer
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: February 22, 2024

Faculty

cover img faculity

Komal Jhaveri, MD, FACP

Associate Attending
Breast Medicine Service and Early Drug Development Service
Section Head, Endocrine Therapy Research Program
Clinical Director, Early Drug Development Service
Department of Medicine
Associate Professor of Medicine
Weill Cornell Medical College
New York, New York

Provided by

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

AstraZeneca

Daiichi Sankyo, Inc.